Compare Amphastar Pharmaceuticals Inc (AMPH) vs Consolidated Edison, Inc. (ED) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Consolidated Edison, Inc. — how do they compare? Amphastar Pharmaceuticals Inc trades at $18.72 (market cap $826.08M), while Consolidated Edison, Inc. trades at $110.82 (market cap $40.95B). The key difference: Consolidated Edison, Inc. is far larger — about 49.6× Amphastar Pharmaceuticals Inc's market cap, and Consolidated Edison, Inc. pays a 3.13% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMPH | ED | |
|---|---|---|
Market Cap | $826.08M | $40.95B |
Sector | Health | Utilities |
52-Week High | $30.81 | $115.46 |
52-Week Low | $16.87 | $95.37 |
Enterprise Value | $1.22B | $67.98B |
Dividend Yield | — | 3.13% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.
The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.
Consolidated Edison (ED) trades at $111.12, up 0.76% on the day, with a bullish technical signal from moving averages and support near $110. The company reported revenue of $16.92B in 2025 with a net income margin of 12.52%, though Q1 2026 EPS missed expectations. Recent news highlights grid upgrades for AI data center demand and a new board member appointment, reinforcing its steady utility profile.
ED offers a defensive investment with a 3.3% dividend yield and 52-year growth streak, but faces risks from capital-intensive grid expansions and interest rate sensitivity. Analyst consensus is cautious with a $103.50 price target below current levels, suggesting limited near-term upside amid high hold ratings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Consolidated Edison, Inc.
Con Ed is a holding company for Consolidated Edison of New York, or CECONY, and Orange & Rockland, or O&R. These utilities provide steam, natural gas, and electricity to customers in southeastern New York—including New York City—and small parts of New Jersey. The two utilities will generate nearly all of Con Ed's earnings once it closes the sale of its clean energy business to RWE. Con Ed's clean energy business owns the second-largest portfolio of utility-scale solar projects in the U.S. Following the sale, Con Ed's only non-utility earnings will come from investments in gas and electric transmission.
Read more on ED →
